Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.
Por:
Quiroga B, Soler MJ, Ortiz A, Vaquera SM, Mantecón CJJ, Useche G, Márquez MGS, Carnerero M, Rodríguez MTJ, Ramos PM, Millán JCRS, Toapanta N, Gracia-Iguacel C, Cervera MCA, Lara NB, Leyva A, Rojas J, Gansevoort RT and de Sequera P
Publicada:
22 sep 2022
Ahead of Print:
12 nov 2021
Resumen:
BACKGROUND: Chronic kidney disease (CKD) patients are at high-risk for severe Covid-19. The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of SARS-CoV-2 vaccines in CKD patients. Safety and immediate humoral response results are reported here. METHODS: Four cohorts of patients were included: kidney transplant (KT) recipients, haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analyzed. RESULTS: 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (p<0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated to KT (OR 20.56, p = 0.001) and to BNT162b2 vaccine (OR 6.03, p = 0.023). CONCLUSION: The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%; suggesting that KT patients require persistent isolation measures and booster doses of a Covid-19 vaccine. Potential differences between Covid-19 vaccines should be explored in prospective controlled studies.
Filiaciones:
Quiroga B:
Nephrology Department, Hospital Universitario de la Princesa, Madrid, Spain
Soler MJ:
Nephrology Department, Vall d'Hebrón University Hospital, Barcelona, Spain
Ortiz A:
IIS-Fundación Jimenez Diaz, School of Medicine, Universidad Autónoma de Madrid, Fundación Renal Iñigo Alvarez de Toledo-IRSIN, REDinREN, Instituto de Investigación Carlos III, Madrid, Spain
Vaquera SM:
Diaverum, Spain
Mantecón CJJ:
Diaverum, Spain
Useche G:
Diaverum, Spain
Márquez MGS:
Nephrology Department, Hospital Universitario Puerto Real, Cádiz, Spain
Carnerero M:
Diaverum, Spain
Rodríguez MTJ:
Nephrology Department, Infanta Leonor University Hospital, Madrid, Spain
Ramos PM:
Nephrology Department, Hospital Universitario de la Princesa, Madrid, Spain
Millán JCRS:
Nephrology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Toapanta N:
Nephrology Department, Vall d'Hebrón University Hospital, Barcelona, Spain
Gracia-Iguacel C:
IIS-Fundación Jimenez Diaz, School of Medicine, Universidad Autónoma de Madrid, Fundación Renal Iñigo Alvarez de Toledo-IRSIN, REDinREN, Instituto de Investigación Carlos III, Madrid, Spain
Cervera MCA:
Nephrology Department, Hospital Universitario de Donostia, San Sebastián, Spain
:
Nephrology Department, Hospital General Universitario de Alicante, Alicante, Spain
Leyva A:
R&D Department, VIRCELL SL, Granada, Spain
Rojas J:
R&D Department, VIRCELL SL, Granada, Spain
Gansevoort RT:
Dept. Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
de Sequera P:
Nephrology Department, Infanta Leonor University Hospital, Madrid, Spain
Green Published, Bronze
|